Therapeutic targets in chronic myeloid leukaemia

被引：25

作者：

Heaney, Nicholas B. ^{[1
]}

Holyoake, Tessa L. ^{[1
]}

机构：

[1] Royal Infirm, ATMU & Canc Div, Sect Expt Haematol & Haemopoiet Stem Cells, Glasgow G31 2ER, Lanark, Scotland

来源：

HEMATOLOGICAL ONCOLOGY | 2007年 / 25卷 / 02期

关键词：

chronic myeloid leukaemia; bcr-abl; haemopoietic stem cell; drug therapy; imatinib mesylate; tyrosine kinase inhibitors; imatinib resistance;

D O I：

10.1002/hon.813

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as a consequence of the formation of the bcr-abl oncogene. The particular molecular basis of this condition has enabled the development of therapies that selectively target diseased cells. The success of the rationally designed first-line therapy imatinib mesylate (IM) is tempered by the problems of disease persistence and resistance. Novel strategies have been identified to take forward therapy in CML and these will be discussed in this review. This work is generated from a review of published literature and contains particular insight into the work performed by our group in this field. Copyright (c) 2007 John Wiley & Sons, Ltd.

引用

页码：66 / 75

页数：10

共 89 条

[1] Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: Role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds [J].

Aichberger, KJ ;

Mayerhofer, M ;

Krauth, MT ;

Vales, A ;

Kondo, R ;

Derdak, S ;

Pickl, WF ;

Selzer, E ;

Deininger, M ;

Druker, BJ ;

Sillaber, C ;

Esterbauer, H ;

Valent, P .

CANCER RESEARCH, 2005, 65 (20) :9436-9444

[2] p27 deregulation in breast cancer: Prognostic significance and implications for therapy [J].

Alkarain, A ;

Jordan, R ;

Slingerland, J .

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2004, 9 (01) :67-80

[3] BCR-ABL nuclear entrapment kills human CMIL cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B [J].

Aloisi, A ;

Di Gregorio, S ;

Stagno, F ;

Guglielmo, P ;

Mannino, F ;

Sormani, MP ;

Bruzzi, P ;

Gambacorti-Passerini, C ;

Saglio, G ;

Venuta, S ;

Giustolisi, R ;

Messina, A ;

Vigneri, P .

BLOOD, 2006, 107 (04) :1591-1598

[4] BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27 Kip1 degradation and proliferation of chronic myelogenous leukemia cells [J].

Andreu, EJ ;

Lledó, E ;

Poch, E ;

Ivorra, C ;

Albero, MP ;

Martínez-Climent, JA ;

Montiel-Duarte, C ;

Rifón, J ;

Pérez-Calvo, J ;

Arbona, C ;

Prósper, F ;

Pérez-Roger, I .

CANCER RESEARCH, 2005, 65 (08) :3264-3272

[5] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[6] Hypusination of eukaryotic imtiation factor 5A (eIF5A):: a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach [J].

Balabanov, Stefan ;

Gontarewicz, Artur ;

Ziegler, Patrick ;

Hartmann, Ulrike ;

Kammer, Winfried ;

Copland, Mhairi ;

Brassat, Ute ;

Priemer, Martin ;

Hauber, Ilona ;

Wilhelm, Thomas ;

Schwarz, Gerold ;

Kanz, Lothar ;

Bokemeyer, Carsten ;

Hauber, Joachim ;

Holyoake, Tessa L. ;

Nordheim, Alfred ;

Bruemmendorf, Tim H. .

BLOOD, 2007, 109 (04) :1701-1711

[7] Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [J].

Bhatia, R ;

Holtz, M ;

Niu, N ;

Gray, R ;

Snyder, DS ;

Sawyers, CL ;

Arber, DA ;

Slovak, ML ;

Forman, SJ .

BLOOD, 2003, 101 (12) :4701-4707

[8] The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy [J].

Blagosklonny, MV ;

Fojo, T ;

Bhalla, KN ;

Kim, JS ;

Trepel, JB ;

Figg, WD ;

Rivera, Y ;

Neckers, LM .

LEUKEMIA, 2001, 15 (10) :1537-1543

[9] Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy [J].

Borthakur, G ;

Kantarjian, H ;

Daley, G ;

Talpaz, M ;

O'Brien, S ;

Garcia-Manero, G ;

Giles, F ;

Faderl, S ;

Sugrue, M ;

Cortes, J .

CANCER, 2006, 106 (02) :346-352

[10] Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations [J].

Bradeen, Heather A. ;

Eide, Christopher A. ;

O'Hare, Thomas ;

Johnson, Kara J. ;

Willis, Stephanie G. ;

Lee, Francis Y. ;

Druker, Brian J. ;

Deininger, Michael W. .

BLOOD, 2006, 108 (07) :2332-2338

← 1 2 3 4 5 6 7 8 9 →